LA JOLLA, Calif., Oct. 9, 2020 /PRNewswire-PRWeb/ — Nanotechnology has long been understood to support many facets of medical science. Researchers and manufacturers are taking this proven technology and are now applying it to one of the fastest growing consumer markets in the world – CBD. And no one has been more active in bringing this tiny technology to CBD consumers than CBD Products Inc, with their new nano inspired brand Cannabinoid Balance.
Having seen that nanotechnology could have a profound effect on absorption rates in the body, the team at CBD Products Inc. turned to NanoZorb™ to help deliver the cannabinoids and terpenes in their Cannabinoid Balance products into the bloodstream quicker.
As with so many things in science, Nano Technology works by increasing the contact area and in turn increases the rate of absorption. By using NanoZorb™Technology in their Cannabinoid Balance products, Anthony Tribunella realized that he
America’s tech giants Google, Amazon, Facebook, and Apple continue apace their march into payments. With Google Pay, Amazon Pay, Facebook Pay, and Apple Pay, they’ve put their brands foremost and use payments to boost on-platform engagement and commerce, reinforcing their centrality in consumers’ lives.
They’ve taken an incrementalist approach, working with incumbent payment networks, processors, and banks, thus far. However, as their payments’ footprints broaden and deepen, that modus vivendi will be stressed.
In particular, Facebook, the world’s leading social-media network outside China, bears watching. It’s starting to roll out Facebook Pay to two billion WhatsApp users and prepping to launch Libra, which could roil the reigning payments ecosystem.
Libra uses stablecoins backed by fiat currencies. If it gets traction it’ll be disruptive. However, building payment-network critical mass, and therefore value and relevance, is hard. Existing systems work. Consumers and merchants are creatures of habit in payments. The graveyard of
Parkinson’s disease is most commonly treated with levodopa, a drug which alleviates the slowing of bodily movements, called bradykinesia, found in Parkinson’s disease patients.
But the benefits of levodopa wear off as the disease progresses. The relationship between its dosage and its effectiveness becomes fuzzy, and high doses can result in dyskinesia, which are involuntary and uncontrollable movements.
To better understand the underlying reasons behind these effects, researchers from the Université de Montréal, University of Bologna, and University of Ottawa created a model of the interactions between levodopa, dopamine, and the basal ganglia, an area of the brain that plays a crucial role in Parkinson’s disease. They discuss their findings in the journal Chaos, from AIP Publishing.
“In Parkinson’s disease, the dopaminergic neurons of the basal ganglia are dying, which results in a lower concentration of dopamine. Levodopa is effective at the beginning of the disease, because it can
Lawyers for TikTok pleaded with a U.S. federal judge on Sunday to delay the Trump Administration’s ban of the popular video sharing program from app stores set to take effect at the end of the day, arguing the move would infringe on First Amendment rights and do irreparable harm to the business.
The 90-minute hearing came after President Donald Trump declared this summer that TikTok was a threat to national security and that it either sold its U.S. operations to U.S. companies or the app would be barred